P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

  • Van Veggel B
  • Van Der Wekken A
  • Hashemi S
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This artice is free to access.

Abstract

Background: Epidermal growth factor receptor (EGFR) exon 20 insertions are identified in 4-10% of al EGFR mutations in non-small cell lung cancer (NSCLC) and are generally associated with primary resistance to first and second generation EGFR tyrosine kinase inhibitors (TKIs). In vitro and preclinical animal studies have shown that osimertinib exerts antitumor activity in EGFR exon 20 insertion positive NSCLC cell lines. We report on a cohort of advanced stage NSCLC patients, harboring an EGFR exon 20 insertion, that was treated with osimertinib. Method(s): 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1. Result(s): Median age was 63 years (range 35 - 81), 71% was female and median number of prior systemic treatments was 1 (range 0 - 3). Ten patients (59%) received prior platinum-based chemotherapy, and 2 patients afatinib, one patient experienced stable disease for 11 months, the other patient showed progression. Among all patients treated with osimertinib, we observed 1 partial response, 13 patients with stable diseases and 3 with progressive disease as best response (ORR 6%). Two patients were still on osimertinib treatment at the cut-off date. Median PFS was 3.7 months (95% CI: 2.3 - 5.4 months). Six of seventeen patients (35%) achieved DCR at five months. Conclusion(s): Osimertinib has limited antitumor activity in patients with EGFR exon 20 mutated NSCLC, with an ORR of 6%. A subset of patients (35%) seems to derive benefit from osimertinib treatment with durable disease control for more than five months. Keywords: EGFR Exon 20 Insertion, Osimertinib [Figure presented]Copyright © 2018

Cite

CITATION STYLE

APA

Van Veggel, B., Van Der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., … De Langen, J. (2018). P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 13(10), S815. https://doi.org/10.1016/j.jtho.2018.08.1437

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free